Cargando…
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
Parkinson’s disease (PD), the second most common progressive neurodegenerative disease, develops and progresses for 10–15 years before the clinical diagnostic symptoms of the disease are manifested. Furthermore, several aspects of PD pathology overlap with other neurodegenerative diseases (NDDs) lin...
Autores principales: | Magalhães, Pedro, Lashuel, Hilal A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307631/ https://www.ncbi.nlm.nih.gov/pubmed/35869066 http://dx.doi.org/10.1038/s41531-022-00357-0 |
Ejemplares similares
-
Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies
por: Kim, Jee Young, et al.
Publicado: (2019) -
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022) -
Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
por: Calabresi, Paolo, et al.
Publicado: (2023) -
Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases
por: Melki, Ronald
Publicado: (2015) -
Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies
por: Sandoval, Ivette M., et al.
Publicado: (2021)